This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pilch, B. Articles by Tazi, J. Search for Related Content PubMed PubMed Citation Articles by Pilch, B. Articles by Tazi, J.

Specific Inhibition of Serine- and Arginine-rich Splicing Factors Phosphorylation, Spliceosome Assembly, and Splicing by the Antitumor Drug NB-506¹

Institut de Génétique Moléculaire, UMR 5535, Centre National de la Recherché Scientifique, IFR 24, Université de Montpellier II, 34293 Montpellier Cedex [B. P., E. A., J. S, J. T.]; Unité MEDIAN, Centre National de la Recherche Scientifique, FRE 2141, UFR de Pharmacie, Université de Reims Champagne-Ardenne, 51096 Reims Cedex [J. F. R.]; and Laboratoire de Pharmacologie Moléculaire Antitumorale du Centre Oscar Lambret et U-124 Institut National de la Santé et de la Recherché Médicale, 59045 Lille Cedex [C. B., M. F.], France

Specific phosphorylation of serine- and arginine-rich pre-mRNA splicing factors (SR proteins) is one of the key determinants regulating splicing events. Several kinases involved in SR protein phosphorylation have been identified and characterized, among which human DNA topoisomerase I is known to have DNA-relaxing activity. In this study, we have investigated the mechanism of splicing inhibition by a glycosylated indolocarbazole derivative (NB-506), a potent inhibitor of both kinase and relaxing activities of topoisomerase I. NB-506 completely inhibits the capacity of topoisomerase I to phosphorylate, in vitro, the human splicing factor 2/alternative splicing factor (SF2/ASF). This inhibition is specific, because NB-506 does not demonstrate activity against other kinases known to phosphorylate SF2/ASF such as SR protein kinase 1 and cdc2 kinase. Importantly, HeLa nuclear extracts competent in splicing but not splicing-deficient cytoplasmic S100 extracts treated with the drug fail to phosphorylate SF2/ASF and to support splicing of pre-mRNA substrates containing SF2/ASF-target sequences. Native gel analysis of splicing complexes revealed that the drug affects the formation of the spliceosome, a dynamic ribonucleoprotein structure where splicing takes place. In the presence of the drug, neither pre-spliceosome nor spliceosome is formed, demonstrating that splicing inhibition occurs at early steps of spliceosome assembly. Splicing inhibition can be relieved by adding phosphorylated SF2/ASF, showing that extracts treated with NB-506 lack a phosphorylating activity required for splicing. Moreover, NB-506 has a cytotoxic effect on murine P388 leukemia cells but not on P388CPT5 camptothecin-resistant cells that carry two point mutations in conserved regions of topoisomerase I gene (Gly361Val and Asp709Tyr). After drug treatment, P388 cells accumulated hypophosphorylated forms of SR proteins and polyadenylated RNA in the nucleus. In contrast, neither SR protein phosphorylation nor polyadenylated mRNA distribution was affected in P388 CPT5-treated cells. Consistently, NB506 treatment altered the mRNA levels and/or splicing pattern of several tested genes (Bcl-X, CD 44, SC35, and Sty) in P388 cells but not in P388 CPT5 cells. The study shows for the first time that indolocarbazole drugs targeting topoisomerase I can affect gene expression by modulating pre-mRNA splicing through inhibition of SR proteins phosphorylation.

This article has been cited by other articles:

				M. L. Hastings, J. Berniac, Y. H. Liu, P. Abato, F. M. Jodelka, L. Barthel, S. Kumar, C. Dudley, M. Nelson, K. Larson, et al. Tetracyclines That Promote SMN2 Exon 7 Splicing as Therapeutics for Spinal Muscular Atrophy Science Translational Medicine, November 4, 2009; 1(5): 5ra12 - 5ra12. [Abstract] [Full Text] [PDF]

				M. Korner and L. J. Miller Alternative Splicing of Pre-mRNA in Cancer: Focus on G Protein-Coupled Peptide Hormone Receptors Am. J. Pathol., August 1, 2009; 175(2): 461 - 472. [Abstract] [Full Text] [PDF]

				M. Malanga, A. Czubaty, A. Girstun, K. Staron, and F. R. Althaus Poly(ADP-ribose) Binds to the Splicing Factor ASF/SF2 and Regulates Its Phosphorylation by DNA Topoisomerase I J. Biol. Chem., July 18, 2008; 283(29): 19991 - 19998. [Abstract] [Full Text] [PDF]

				L. Shkreta, U. Froehlich, E. R. Paquet, J. Toutant, S. A. Elela, and B. Chabot Anticancer drugs affect the alternative splicing of Bcl-x and other human apoptotic genes Mol. Cancer Ther., June 1, 2008; 7(6): 1398 - 1409. [Abstract] [Full Text] [PDF]

				T. Revil, J. Toutant, L. Shkreta, D. Garneau, P. Cloutier, and B. Chabot Protein Kinase C-Dependent Control of Bcl-x Alternative Splicing Mol. Cell. Biol., December 15, 2007; 27(24): 8431 - 8441. [Abstract] [Full Text] [PDF]

				J. Barbier, M. Dutertre, D. Bittencourt, G. Sanchez, L. Gratadou, P. de la Grange, and D. Auboeuf Regulation of H-ras Splice Variant Expression by Cross Talk between the p53 and Nonsense-Mediated mRNA Decay Pathways Mol. Cell. Biol., October 15, 2007; 27(20): 7315 - 7333. [Abstract] [Full Text] [PDF]

				A. Lansiaux, S. Leonce, L. Kraus-Berthier, C. Bal-Mahieu, R. Mazinghien, S. Didier, M.-H. David-Cordonnier, P. Hautefaye, G. Lavielle, C. Bailly, et al. Novel Stable Camptothecin Derivatives Replacing the E-Ring Lactone by a Ketone Function Are Potent Inhibitors of Topoisomerase I and Promising Antitumor Drugs Mol. Pharmacol., August 1, 2007; 72(2): 311 - 319. [Abstract] [Full Text] [PDF]

				J. Soret, N. Bakkour, S. Maire, S. Durand, L. Zekri, M. Gabut, W. Fic, G. Divita, C. Rivalle, D. Dauzonne, et al. Selective modification of alternative splicing by indole derivatives that target serine-arginine-rich protein splicing factors PNAS, June 14, 2005; 102(24): 8764 - 8769. [Abstract] [Full Text] [PDF]

				J. Tazi, N. Bakkour, J. Soret, L. Zekri, B. Hazra, W. Laine, B. Baldeyrou, A. Lansiaux, and C. Bailly Selective Inhibition of Topoisomerase I and Various Steps of Spliceosome Assembly by Diospyrin Derivatives Mol. Pharmacol., April 1, 2005; 67(4): 1186 - 1194. [Abstract] [Full Text] [PDF]

				J. P. Venables Aberrant and Alternative Splicing in Cancer Cancer Res., November 1, 2004; 64(21): 7647 - 7654. [Abstract] [Full Text] [PDF]

				M. Muraki, B. Ohkawara, T. Hosoya, H. Onogi, J. Koizumi, T. Koizumi, K. Sumi, J.-i. Yomoda, M. V. Murray, H. Kimura, et al. Manipulation of Alternative Splicing by a Newly Developed Inhibitor of Clks J. Biol. Chem., June 4, 2004; 279(23): 24246 - 24254. [Abstract] [Full Text] [PDF]

				S. Solier, A. Lansiaux, E. Logette, J. Wu, J. Soret, J. Tazi, C. Bailly, L. Desoche, E. Solary, and L. Corcos Topoisomerase I and II Inhibitors Control Caspase-2 Pre-Messenger RNA Splicing in Human Cells Mol. Cancer Res., January 1, 2004; 2(1): 53 - 61. [Abstract] [Full Text] [PDF]

				J. Soret, M. Gabut, C. Dupon, G. Kohlhagen, J. Stevenin, Y. Pommier, and J. Tazi Altered Serine/Arginine-Rich Protein Phosphorylation and Exonic Enhancer-Dependent Splicing in Mammalian Cells Lacking Topoisomerase I Cancer Res., December 1, 2003; 63(23): 8203 - 8211. [Abstract] [Full Text] [PDF]

				M. Facompre, C. Tardy, C. Bal-Mahieu, P. Colson, C. Perez, I. Manzanares, C. Cuevas, and C. Bailly Lamellarin D: A Novel Potent Inhibitor of Topoisomerase I Cancer Res., November 1, 2003; 63(21): 7392 - 7399. [Abstract] [Full Text] [PDF]

				N. A. Faustino and T. A. Cooper Pre-mRNA splicing and human disease Genes & Dev., February 15, 2003; 17(4): 419 - 437. [Full Text] [PDF]

				S. Stamm Signals and their transduction pathways regulating alternative splicing: a new dimension of the human genome Hum. Mol. Genet., October 1, 2002; 11(20): 2409 - 2416. [Abstract] [Full Text] [PDF]

				C. Carrasco, M. Facompre, J. D. Chisholm, D. L. Van Vranken, W. D. Wilson, and C. Bailly DNA sequence recognition by the indolocarbazole antitumor antibiotic AT2433-B1 and its diastereoisomer Nucleic Acids Res., April 15, 2002; 30(8): 1774 - 1781. [Abstract] [Full Text] [PDF]

				M. H. Woo, J. R. Vance, A. R. O. Marcos, C. Bailly, and M.-A. Bjornsti Active Site Mutations in DNA Topoisomerase I Distinguish the Cytotoxic Activities of Camptothecin and the Indolocarbazole, Rebeccamycin J. Biol. Chem., February 1, 2002; 277(6): 3813 - 3822. [Abstract] [Full Text] [PDF]